Piramal Pharma Reports Q1 Growth; Biodeal Exit and RPG Life Sciences Expands API Exports
Piramal Pharma Limited reported a 17% revenue increase and a 72% rise in EBITDA for Q1 FY27, driven by growth across its CDMO, Complex Hospital Generics, and Consumer Healthcare businesses. The company maintained high-quality standards with a successful US FDA inspection. Separately, Piramal Alternatives exited its investment in Biodeal Pharmaceuticals, achieving over 20% IRR amid strong revenue and margin growth. RPG Life Sciences is expanding its API exports, focusing on Mexico and emerging markets, following the resumption of operations at its Navi Mumbai facility and exploring acquisitions.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (74/100). Lens Score 39/100.
Outlets measured: thetribune, thetribune, thehindu, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (70–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 29 Jul, 09:17 am. Other outlets followed.